© Reuters Eli Lilly (LLY): Diabetes & Obesity President to retire; shares dip
Eli Lilly and Company (NYSE:) announced today that Mike Mason, who has served as executive vice president (EVP) and president of Lilly Diabetes and Obesity for 34 years, will retire at the end of 2023.
Shares fell 1% on the announcement.
Patrik Jonsson will take over leadership of Lilly Diabetes and Obesity while continuing his role as EVP and president of Lilly USA.
“As we embark on this exciting new chapter of growth for our company, I’ve never been more confident about our ability to deliver life-changing medicines to the patients who need them,” said David A. Ricks, Lilly’s chair and CEO. “The deep experience of our leadership team ensures that we will continue to accelerate our efforts in effective, innovative ways.”
Moreover, Daniel Skovronsky, the company’s chief scientific officer and president of Lilly Research Laboratories, will assume the additional position of president of Lilly Immunology, taking over from Jonsson.
Read the full article here